^
    2d
    PrE1005: Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma (clinicaltrials.gov)
    P3, N=500, Not yet recruiting, PrECOG, LLC.
    New P3 trial
    |
    lenalidomide • bortezomib • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • Blenrep (belantamab mafodotin-blmf)
    4d
    Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse (clinicaltrials.gov)
    P2, N=80, Not yet recruiting, National Cancer Institute (NCI) | Initiation date: Oct 2025 --> Jan 2026
    Trial initiation date
    |
    carfilzomib • pomalidomide • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • Tecvayli (teclistamab-cqyv) • Hemady (dexamethasone tablets) • dexamethasone injection
    7d
    FT576 in Subjects With Multiple Myeloma (clinicaltrials.gov)
    P1, N=31, Completed, Fate Therapeutics | Active, not recruiting --> Completed
    Trial completion
    |
    cyclophosphamide • fludarabine IV • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • FT576
    13d
    CARTITUDE-2: A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma (clinicaltrials.gov)
    P2, N=210, Active, not recruiting, Janssen Research & Development, LLC | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    lenalidomide • bortezomib • dexamethasone • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • Carvykti (ciltacabtagene autoleucel) • dexamethasone injection
    16d
    Real MM: STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA (clinicaltrials.gov)
    P4, N=450, Active, not recruiting, University of Turin, Italy | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    lenalidomide • bortezomib • prednisone • dexamethasone • melphalan • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • dexamethasone injection
    24d
    ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma (clinicaltrials.gov)
    P2, N=160, Not yet recruiting, Massachusetts General Hospital
    New P2 trial
    |
    clonoSEQ
    |
    lenalidomide • bortezomib • Elrexfio (elranatamab-bcmm) • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • dexamethasone injection
    28d
    Home Based Daratumumab Administration for Patients With Multiple Myeloma (clinicaltrials.gov)
    P4, N=20, Completed, Thomas Jefferson University | Phase classification: P1 --> P4
    Phase classification
    |
    Darzalex Faspro (daratumumab and hyaluronidase-fihj)
    1m
    CARTITUDE-4: A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma (clinicaltrials.gov)
    P3, N=419, Active, not recruiting, Janssen Research & Development, LLC | Trial completion date: Sep 2036 --> Apr 2029
    Trial completion date • IO biomarker
    |
    lenalidomide • bortezomib • cyclophosphamide • dexamethasone • pomalidomide • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • Carvykti (ciltacabtagene autoleucel)
    1m
    AQUARIUS: A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis (clinicaltrials.gov)
    P2, N=151, Active, not recruiting, Janssen Research & Development, LLC | Trial primary completion date: Mar 2026 --> May 2025
    Trial primary completion date
    |
    bortezomib • cyclophosphamide • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • dexamethasone injection
    1m
    A Study of TTI-622 in Combination With Daratumumab Hyaluronidase-fihj in People With Multiple Myeloma (clinicaltrials.gov)
    P1, N=7, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Oct 2025 --> Oct 2026 | Trial primary completion date: Oct 2025 --> Oct 2026
    Trial completion date • Trial primary completion date
    |
    Darzalex Faspro (daratumumab and hyaluronidase-fihj) • maplirpacept (TTI-622)
    2ms
    A Phase III, Randomized, Multicenter Study Comparing Daratumumab-Lenalidomide-Dexamethasone (DRD) versus Bortezomib-Lenalidomide-Dexamethasone (VRD) in Transplant-Ineligible, Newly Diagnosed Multiple Myeloma Patients (ChiCTR2500110356)
    P3, N=440, Recruiting, The First Affiliated Hospital, Zhejiang University School of Medicine; The First Affiliated Hospital, Zhejiang University School of Medicine
    New P3 trial
    |
    lenalidomide • bortezomib • dexamethasone • Darzalex Faspro (daratumumab and hyaluronidase-fihj)
    2ms
    LINKER-MM5: A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (clinicaltrials.gov)
    P3, N=915, Not yet recruiting, Regeneron Pharmaceuticals
    New P3 trial
    |
    bortezomib • carfilzomib • dexamethasone • pomalidomide • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • Lynozyfic (linvoseltamab-gcpt)